Quality of evidence supporting the role of Chinese herbal medicine for the treatment of poststroke depression: A protocol for systematic review and meta-analysis

Medicine (Baltimore). 2022 Jan 28;101(4):e28707. doi: 10.1097/MD.0000000000028707.

Abstract

Background: Poststroke depression (PSD) is a syndrome that occurs after stroke. The efficacy of Chinese herbal medicine (CHM) for PSD has also received widespread attention, but there is still a lack of clinical evidence because this overview evaluates the published meta-analyses (MAs)/Systematic reviews (SRs). To provide evidence for the clinical application of CHM in the treatment of PSD.

Methods: Two researchers searched 7 databases for SRs/MAs which are about randomized controlled trials on CHM for PSD. Two investigators use the systematic review assessment tool (AMSTAR-2), the risk of bias in systematic scale, the list of preferred reporting items for systematic reviews and meta-analysis, and the classification of recommended assessments for evaluation, development and evaluation system to assess the included SRs/MAs.

Results: Our findings will be published in peer-reviewed journals.

Conclusion: This study provides evidence-based medical evidence for the impact of CHM on PSD.

Registration number: INPLASY202210001.

MeSH terms

  • Databases, Factual
  • Depression / drug therapy*
  • Depression / etiology
  • Drugs, Chinese Herbal / therapeutic use*
  • Humans
  • Meta-Analysis as Topic
  • Systematic Reviews as Topic

Substances

  • Drugs, Chinese Herbal